2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2769 Choosing between acalabrutinib vs zanubrutinib in CLL: A propensity score-matched comparison of cardiovascular and bleeding outcomes

Kim Abbegail Tan Aldecoa, MD, Catherine C. Coombs, MD2, Helen Ma, MD, MS3
1 University of California, Irvine, 101 The City Drive South,, California, United States
2 University of California, Irvine, 101 The City Drive South,, California, United States
3 University of California, Irvine, 101 The City Drive South,, California, United States

INTRODUCTION:
Acalabrutinib and zanubrutinib are now preferred second-generation covalent Bruton tyrosine kinase inhibitors (BTKi) for both treatment-naive and relapsed/refractory chronic lymphocytic leukemia (CLL). Although both demonstrate improved safety than ibrutinib, clinicians frequently face uncertainty when selecting between these agents because comparative head-to-head real-world data on cardiovascular and bleeding toxicities are limited. We performed a large propensity score–matched (PSM) analysis to compare cardiovascular, hemorrhagic, and clinical outcomes associated with acalabrutinib and zanubrutinib.

METHODS:

In this retrospective cohort study, adults (≥18 years) with CLL treated with acalabrutinib or zanubrutinib were identified from the TriNetX Global Network, a federated electronic health record of de-identified patients across multiple healthcare organizations. Patients were analyzed separately by treatment setting: treatment-naive and relapsed/refractory (R/R). Index date was BTKi initiation, with patients assigned to mutually exclusive cohorts based on initial BTKi received. Patients with baseline atrial fibrillation/flutter (AF) or study outcomes before BTKi initiation were excluded. Primary outcomes were AF and major hemorrhage [gastrointestinal (GI), intracranial hemorrhage (ICH), retroperitoneal, hemothorax, hemoperitoneum, and hemopericardium]. Secondary outcomes were ventricular tachyarrhythmias, hospitalization, and all-cause mortality. Cohorts were matched by PSM on baseline demographics, clinically relevant comorbidities, and prior treatment (for R/R). Time-to-event outcomes were evaluated over 3 years using Kaplan-Meier and Cox proportional hazards regression. Sensitivity analyses included follow-up at 1 and 2 years, comparison with ibrutinib, and an exploratory analysis restricted to patients with prior ibrutinib exposure.

RESULTS:

Among treatment-naive CLL patients, 1,545 remained in each cohort after PSM (pre-PSM: acalabrutinib n=3,224; zanubrutinib n=1,555; mean age 72y; 65-66% male; 79-80% White; 8-9% Black). No significant difference in AF risk was observed at 1 or 2 years. By 3 years, acalabrutinib was associated with a higher risk of AF than zanubrutinib (10.2% vs 6.3%, HR 1.45,95% CI 1.10-1.90, p=0.0075), whereas major hemorrhage was comparable between groups (6.8% vs 5.8%, HR 0.99, 95% CI 0.74-1.34, p=0.98), including GI bleeding (3.0% vs 2.9%, HR 0.87, 95% CI 0.57-1.32, p=0.52) and ICH (2.0% vs 1.2%, HR 1.48, 95% CI 0.82–2.65, p=0.18). Ventricular tachyarrhythmias (2.1% vs 1.8%, HR 0.99, 95% CI 0.59-1.66, p=0.96), hospitalization (26.1% vs 23.8%, HR 1.00, 95% CI 0.82-1.23,p=0.97) and mortality (12.7% vs 10.5%, HR 1.04,95% CI 0.84-1.28,p=0.73) were also similar.

Among R/R CLL patients, 1,814 remained in each cohort (pre-PSM: acalabrutinib n=4,100; zanubrutinib n=1,823; mean age 72y; 63% male; 81% White; 7.4-8.5% Black). No significant difference in AF risk was observed at 1 or 2 years. By 3 years, acalabrutinib was associated with higher risk of AF than zanubrutinib (10.4% vs. 6.8%, HR 1.30, 95% CI 1.03-1.71, p=0.02). Major hemorrhage (7.3% vs 6.9%, HR 0.90, 95% CI 0.69-1.16, p=0.42) and all other secondary outcomes were comparable, including GI bleeding (3.9% vs 3.3%, HR 1.04, 95% CI 0.73-1.50, p=0.82), ICH (1.6% vs 1.7%,HR 0.78, 95% CI 0.47-1.32, p=0.36), ventricular tachyarrhythmias (2.4% vs 2.0%, HR 1.02, 95% CI 0.65-1.59, p=0.95), hospitalization (26% vs 22%, HR 1.12, 95% CI 0.91-1.37, p=0.28), and mortality (14.5% vs 10.0%, HR 1.19, 95% CI 0.98-1.44, p=0.07). Among patients previously exposed to ibrutinib, exploratory analyses demonstrated no significant difference in AF (10.2% vs 8.9%, HR 1.04, 95% CI 0.66-1.64, p=0.86) or major hemorrhage (8.2% vs 5.1%, HR 1.40, 95% CI 0.82-2.39, p=0.22) between groups.

In sensitivity analyses using ibrutinib as the comparator, both second-generation BTKi demonstrated improved cardiovascular and bleeding safety, with significantly lower rates of AF, major hemorrhage, GI bleeding, hospitalization, and 3-year mortality

CONCLUSION:

In this large real-world cohort, zanubrutinib was associated with a lower risk of AF than acalabrutinib in both treatment-naive and R/R CLL, whereas major bleeding risks remained comparable. These findings provide comparative real-world safety data to guide clinician selection between the two agents, particularly for patients at increased cardiovascular risk. Prospective studies are warranted to confirm these findings.
Kim Abbegail Tan Aldecoa, MD: No relevant conflicts of interest to declare.